RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 OPTiM Study Results
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 17
OP 17
DO 10.1177/155989771306011
UL http://mdc.sagepub.com/content/13/6/17.1.abstract
AB Results from the Efficacy and Safety Study of OncoVEX Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to GM-CSF in Melanoma [OPTiM; NCT00769704; Andtbacka RHI et al. J Clin Oncol 2013 (suppl; abstr LBA9008)] showed that a genetically modified version of herpes simplex virus type 1 (talimogene laherparepvec), is safe and improves durable response rate in patients with unresectable stage IIIB-IV melanoma.